세계의 화학요법 유발 메스꺼움 및 구토(CINV) 시장 보고서(2025년)

Chemotherapy-induced nausea and vomiting (CINV) is a condition characterized by the sensation of nausea and vomiting, often arising as a side effect of chemotherapy treatment. This common side effect can significantly impact the quality of life and treatment outcomes for many cancer patients. Fortunately, CINV can be effectively managed and treated through medications and lifestyle adjustments.

CINV presents in various forms, including injectables, oral medications, and transdermal patches. Injectables are chemical substances administered via injection to produce various therapeutic effects. Medications used for CINV management belong to different drug classes, such as 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. The risk of developing CINV varies, with emetogenic risks categorized into highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), and low emetogenic chemotherapy (LEC). These treatments and medications are distributed through multiple channels, including CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores. They find application in various medical fields such as gynecology, urology, gastrointestinal surgery, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chemotherapy-induced nausea and vomiting (CINV) market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced nausea and vomiting (CINV) market statistics, including chemotherapy-induced nausea and vomiting (CINV) industry global market size, regional shares, competitors with a chemotherapy-induced nausea and vomiting (CINV) market share, detailed chemotherapy-induced nausea and vomiting (CINV) market segments, market trends and opportunities and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (CINV) industry. This chemotherapy-induced nausea and vomiting (CINV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.92 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $4.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of NK1 receptor antagonists and 5-HT3 inhibitors sourced from India and Israel, exacerbating treatment side effects and increasing antiemetic medication costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is set to drive the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the foreseeable future. The proliferation of cancer occurs when certain cells in the body undergo uncontrolled growth and spread to other parts of the body. With cancer cases on the rise, there is a growing impetus to develop more effective and targeted antiemetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on managing CINV has led to advancements in understanding its underlying mechanisms and the creation of innovative therapies. For example, as of January 2023, the American Cancer Society (ACS) anticipates around 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) in the United States for 2023. Consequently, the increasing prevalence of cancer will be a driving force behind the chemotherapy-induced nausea and vomiting (CINV) market.

The growth of the chemotherapy-induced nausea and vomiting (CINV) market is expected to be driven by the increasing favorable regulatory initiatives. Regulatory initiatives are actions undertaken by regulatory bodies to develop, enforce, or implement regulations. These initiatives are aimed at enhancing the prevention and management of chemotherapy-induced nausea and vomiting (CINV) by establishing guidelines and policies. For example, in October 2024, the U.S. Food and Drug Administration (FDA), a federal agency focused on public health protection, reported that in 2023, its Center for Drug Evaluation and Research (CDER) approved 55 new drugs specifically for chemotherapy-induced nausea and vomiting (CINV). As a result, the growing favorable regulatory initiatives are propelling the growth of the CINV market.

Major companies in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on new product innovations, such as fixed intravenous antiemetics, to gain a competitive edge. A fixed intravenous antiemetic refers to a predetermined dose of medication delivered via IV to prevent or treat nausea and vomiting, commonly used in chemotherapy or post-surgery contexts. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical manufacturer, launched AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination designed to prevent chemotherapy-induced nausea and vomiting (CINV). This product combines netupitant and palonosetron, addressing both acute and delayed phases of nausea and vomiting. It offers single-dose convenience, higher complete response rates, and improved quality of life for cancer patients. Clinical studies indicate it is especially effective for patients undergoing highly emetogenic chemotherapy.

In January 2022, Cumberland Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical firm, acquired SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc. for $13.5 million. This acquisition granted Cumberland full control over the U.S. rights to SANCUSO, a chemotherapy-induced nausea and vomiting (CINV) drug. This included responsibility for marketing, promotion, distribution, manufacturing, and medical support operations related to the product. Kyowa Kirin Inc. is a U.S.-based subsidiary of Kyowa Kirin Co. Ltd. in Japan, a specialty pharmaceutical company that specializes in developing innovative medicines used for preventing CINV.

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy-induced nausea and vomiting (CINV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced nausea and vomiting (cinv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced nausea and vomiting (cinv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemotherapy-induced nausea and vomiting (cinv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Form: Injectables; Oral; Transdermal Patches
• 2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
• 3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
• 4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
• 5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
• Subsegments:
• 1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
• 2) By Oral: Tablets; Capsules; Liquid Formulations
• 3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc; Baxter International Inc.; Teva Pharmaceuticals Industries Ltd.; Bausch Health Companies Inc.; Eisai Co. Ltd.; Jazz Pharmaceuticals plc; Ono Pharmaceutical Co. Ltd.; Dr. Reddy's Laboratories Ltd.; Kyowa Kirin Inc.; Amneal Pharmaceuticals Inc.; Mundipharma International Limited; Insys Therapeutics Inc.; Lupin Limited; Helsinn Holding S.A.; Heron Therapeutics Inc.; Camurus AB; Cadila Pharmaceuticals Limited; Acacia Pharma Ltd.; Soligenix Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics

3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies

4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate Analysis
• 5.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Total Addressable Market (TAM)

6. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation

• 6.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectables
• Oral
• Transdermal Patches
• 6.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-HT3 Receptor Antagonists
• Neurokinin-1 Receptor Antagonists
• Corticosteroids
• Cannabinoids
• Other Drug Class
• 6.3. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Highly Emetogenic Chemotherapy (HEC)
• Moderately Emetogenic Chemotherapy (MEC)
• Low Emetogenic Chemotherapy (LEC)
• 6.4. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CINV Hospitals
• Cancer Research Institute
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• 6.5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology
• Urology
• Gastrointestinal Surgery
• Other Applications
• 6.6. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Injectables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Solutions
• Intramuscular (IM) Injections
• 6.7. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquid Formulations
• 6.8. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Sub-Segmentation Of Transdermal Patches, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fentanyl Patches
• Scopolamine Patches

7. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional And Country Analysis

• 7.1. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 8.1. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 9.1. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 9.2. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 10.1. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 11.1. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 11.2. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 12.1. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 13.1. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 14.1. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 14.2. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 15.1. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 15.2. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 16.1. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 17.1. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 18.1. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 19.1. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 20.1. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 21.1. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 21.2. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 22.1. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 23.1. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 23.2. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 24.1. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 24.2. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 25.1. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 25.2. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 26.1. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 26.2. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 27.1. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 28.1. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 28.2. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market

• 29.1. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
• 29.2. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market, Segmentation By Emetogenic Risk, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape
• 30.2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Baxter International Inc.
• 31.4. Teva Pharmaceuticals Industries Ltd.
• 31.5. Bausch Health Companies Inc.
• 31.6. Eisai Co. Ltd.
• 31.7. Jazz Pharmaceuticals plc
• 31.8. Ono Pharmaceutical Co. Ltd.
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Kyowa Kirin Inc.
• 31.11. Amneal Pharmaceuticals Inc.
• 31.12. Mundipharma International Limited
• 31.13. Insys Therapeutics Inc.
• 31.14. Lupin Limited
• 31.15. Helsinn Holding S.A.

32. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

34. Recent Developments In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

35. Chemotherapy-Induced Nausea and Vomiting (CINV) Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer